VXRT Stock Chart & Stats
$12.00
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$12.00 - $12.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$2.09B
Enterprise Value$97.70
Total Cash (Recent Filing)$61.02M
Total Debt (Recent Filing)$7.97M
Price to Earnings (P/E)3.6
Beta-0.16
Next Earnings
Jul 30, 2026EPS Estimate
-2.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding242,044,850
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.92
Price to Sales (P/S)0.34
P/FCF Ratio10.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Favorable 12‑month Safety Data For Oral COVID VaccineRobust safety readouts from a ~400‑participant sentinel cohort materially lower regulatory and clinical development risk for the oral vaccine platform. Backing by substantial federal funds and a large main cohort supports continued program execution, partnership and commercialization potential over the next 2–6 months and beyond.
Conservatively Levered Balance Sheet With Improved LeverageLower debt and a stronger equity base provide financial flexibility to fund clinical milestones and absorb program timing variability. Improved leverage reduces near‑term refinancing pressure and supports sustaining R&D investments and partner engagement while the company pursues pivotal trial readouts.
Governance Refresh And Experienced Biotech Leadership AddedA formal governance reset and the addition of a seasoned vaccine developer strengthen board oversight, investor engagement and regulatory strategy. Institutionalizing clinical and regulatory committees and stockholder engagement should improve decisionmaking and reduce activist friction, aiding long‑term program execution.
Bears Say
No Approved Commercial Product; Outcomes Dependent On Trial MilestonesWith no marketed products, the company’s long‑term prospects hinge on successful clinical efficacy and regulatory approvals. This creates binary value drivers: program failures or delays can materially impair future revenue generation and force additional financing, making near‑term fundamentals contingent on trial outcomes.
Government Funding Instability After BARDA Partial TerminationReliance on BARDA and similar non‑dilutive funding exposes the program to scope cuts and timeline shifts. The partial termination reduced overall funding and enrollment, increasing execution risk and the need to reallocate resources or secure supplemental funding to preserve statistical power and regulatory timelines.
Historic Multi‑year Cash Burn Makes Recent Turnaround Durability UncertainAlthough free cash flow and profitability improved recently, prior multi‑year cash burn and the modest conversion of reported income to operating cash flow indicate the turnaround may be fragile. Future adverse trial results or funding gaps could quickly reopen cash shortfalls and raise refinancing needs.
VXRT FAQ
What was Vaxart’s price range in the past 12 months?
Vaxart lowest stock price was $12.00 and its highest was $12.00 in the past 12 months.
What is Vaxart’s market cap?
Vaxart’s market cap is $2.09B.
When is Vaxart’s upcoming earnings report date?
Vaxart’s upcoming earnings report date is Jul 30, 2026 which is in 3 days.
How were Vaxart’s earnings last quarter?
Vaxart released its earnings results on May 07, 2026. The company reported $0.35 earnings per share for the quarter, the consensus estimate of $0.35 by $0.
Is Vaxart overvalued?
According to Wall Street analysts Vaxart’s price is currently Undervalued.
Does Vaxart pay dividends?
Vaxart does not currently pay dividends.
What is Vaxart’s EPS estimate?
Vaxart’s EPS estimate is -2.1.
How many shares outstanding does Vaxart have?
Vaxart has 242,044,850 shares outstanding.
What happened to Vaxart’s price movement after its last earnings report?
Vaxart reported an EPS of $0.35 in its last earnings report, expectations of $0.35. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vaxart?
Currently, no hedge funds are holding shares in MX:VXRT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vaxart Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.32%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
13.56%
Trailing 12-Months
Company Description
Vaxart
Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
VXRT Earnings Call
Q1 2026
0:00 / 0:00